Terumo Corp

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Terumo Corp. engages in the manufacturing and sale of medical products and equipment. It operates through the following segments: Cardiac and Vascular Company, General Hospital Company, and Blood Management Company. The Cardiac and Vascular Company segment offers services and treatments including cardiac and vascular surgery and interventional therapies performed inside blood vessels. The General Hospital Company segment provides infusion and closed anticancer drug infusion systems, measuring devices system with communication functions, diabetes management, adhesion barrier, and peritoneal dialysis. The Blood Management Company segment offers a combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. The company was founded by Shibasaburo Kitasato on September 17, 1921 and is headquartered in Tokyo, Japan.

Terumo (TRUMY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Terumo (TRUMY) Moves to Strong Buy: Rationale Behind the Upgrade

Cipher Mining

Sitio Royalties Corp

TRUMY, CIFR and STR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 28, 2023.

Best Momentum Stocks to Buy for March 28th

Daqo New Energy

Reynolds Consumer Products

Xerox

XRX, REYN, TRUMY, DQ and STR have been added to the Zacks Rank #1 (Strong Buy) List on March 28, 2023.

New Strong Buy Stocks for March 28th

Terumo Corp. (TRUMY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

What Makes Terumo Corp. (TRUMY) a Good Fit for 'Trend Investing'

Terumo Corp. (TRUMY) is on the Move, Here's Why the Trend Could be Sustainable

Terumo Corporation (TRUMF) Q3 2024 Earnings Call Transcript

Terumo Corp. (TRUMY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Recent Price Trend in Terumo Corp. (TRUMY) is Your Friend, Here's Why

Terumo's (TRUMY) coil system boasts a soft, universal-shaped platinum and hydrogel composition, which sets it apart in the peripheral coil market.

Terumo (TRUMY) Launches AZUR HydroPack in Embolotherapy Space

Terumo Corporation (OTCPK:TRUMF) Q2 2024 Earnings Conference Call November 15, 2023 6:00 AM ET Company Participants Naoki Muto - Chief Accounting Officer & Chief Financial Officer Shinjiro Sato - Chief Executive Officer Conference Call Participants Naoki Muto Hello. I am the CAFO, Muto.

Terumo Corporation (TRUMF) Q2 2024 Earnings Call Transcript

The SOFIA EX 5F Catheter by Terumo's (TRUMY) MicroVention boasts a new design to enhance trackability.

Terumo's (TRUMY) MicroVention Enters Transradial Access Space

Icecure Medical Ltd

Professor Eisuke Fukuma, who has performed over 600 ProSense breast cancer cryoablation procedures, led a cryoablation symposium with ProSense IceCure joined its exclusive regional distributor, Terumo, to exhibit the ProSense System to physicians seeking minimally invasive alternatives to lumpectomy   CAESAREA, Israel , Aug. 21, 2023 /PRNewswire/ -- IceCure Medical LTD. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, recently participated in the 16th Thai Breast Symposium in Bangkok, Thailand, which was hosted by the Thai Breast Surgeons Society.

IceCure Medical Continues to Experience Growing Global Interest in ProSense: Featured at the 16th Thai Breast Symposium

Terumo Corporation (OTCPK:TRUMF) Q1 2024 Earnings Conference Call August 9, 2023 4:15 AM ET Company Participants Naoki Muto - Chief Accounting and Financial Officer and Group Executive Officer Conference Call Participants Naoki Muto I am the CAFO, Muto. I will give an overview of our earnings results for the first quarter of the fiscal year ending March 31, 2024.

Terumo Corporation (TRUMF) Q1 2024 Earnings Call Transcript

Terumo Corporation (OTCPK:TRUMF) Q4 2023 Results Conference Call May 15, 2023 4:30 AM ET Company Participants Naoki Muto - Chief Accounting and Financial Officer Antoinette Gawin - President & Chief Executive Officer Naoki Muto Hello. I am the CAFO, Muto.

Terumo Corporation (TRUMF) Q4 2023 Earnings Call Transcript

Terumo Corporation (OTCPK:TRUMF) Q3 2023 Earnings Conference Call February 9, 2023 3:00 AM ET Company Participants Naoki Muto - Chief Accounting and Financial Officer Conference Call Participants Naoki Muto Hello. I am the CAFO, Muto.

Terumo Corporation (TRUMF) Q3 2023 Earnings Call Transcript

Terumo Corporation A. (OTCPK:TRUMF) Q2 2022 Earnings Conference Call November 10, 2022 7:00 AM ET Company Participants Shinjiro Sato - President & Chief Executive Officer Naoki Muto - Chief Accounting & Financial Officer Conference Call Participants Shinjiro Sato Good evening, everybody.

Terumo Corporation A. (TRUMF) Q2 2022 Earnings Call Transcript

Terumo Corporation (OTCPK:TRUMF) Q1 202 Earnings Conference Call August 9, 2022 4:00 AM ET Company Participants Naoki Muto - Chief Accounting and Financial Officer Conference Call Participants Naoki Muto I am the CAFO, Muto. I will now explain the First Quarter Results for the Fiscal Year-Ending March 2023.

Terumo Corporation's (TRUMF) Q1 2022 Results - Earnings Call Transcript

Terumo Corporation (OTCPK:TRUMF) Q4 2021 Earnings Conference Call May 13, 2022 7:00 AM ET Company Participants Naoki Muto - Chief Accounting and Financial Officer Shinjiro Sato - President and CEO Conference Call Participants Operator I am the CFO, Muto. I will now explain the results for the fiscal year ending March 2022.

Terumo Corporation (TRUMF) CEO Shinjiro Sato on Q4 2021 Results - Earnings Call Transcript

Terumo Corporation (TRUMF) Q3 2021 Results - Earnings Call Transcript

Terumo Corporation (TRUMF) CEO Shinjiro Sato on Q2 2022 Results - Earnings Call Transcript

Terumo Corporation (TRUMF) Q1 2022 Results - Earnings Call Transcript

Terumo Corporation (TRUMF) Management on Q3 2021 Results - Earnings Call Transcript

Terumo Corporation (TRUMF) CEO Naoki Muto on Q1 2021 Results - Earnings Call Transcript

Terumo Corporation (TRUMF) CEO Shinjiro Sato on Q4 2020 Results - Earnings Call Transcript

Marker Therapeutics Inc

The Food and Drug Administration (FDA) on Friday issued emergency use authorizations to blood purification devices manufactured by Terumo Corp. and Marker Therapeutics Inc.

News for Terumo Corp Stock (TRUMY)